CPDR001X2X01B
NCT04058756
JCP069
Rollover Study for Continued Safety and Tolerability in Subjects Treated with Spartalizumab Alone or in Combination With Other Study Treatments
Status:
Closed to Accrual
I
Phase
Roll over
Line of Therapy
Disease Stage
Biomarker(s)
N/A
Investigational
Product
Spartalizumab
Treatment Arms
o Experimental: Spartalizumab